CareDx (CDNA) Projected to Post Earnings on Tuesday

CareDx (NASDAQ:CDNA) is expected to post its Q3 2025 results after the market closes on Tuesday, November 4th. Analysts expect CareDx to post earnings of $0.13 per share and revenue of $95.25 million for the quarter. Parties may review the information on the company’s upcoming Q3 2025 earningreport for the latest details on the call scheduled for Tuesday, November 4, 2025 at 4:30 PM ET.

CareDx (NASDAQ:CDNA) last announced its quarterly earnings results on Wednesday, August 6th. The company reported ($0.16) EPS for the quarter, missing the consensus estimate of $0.12 by ($0.28). The business had revenue of $90.51 million during the quarter, compared to analyst estimates of $90.72 million. CareDx had a net margin of 17.97% and a return on equity of 18.03%. The business’s revenue for the quarter was down 6.1% on a year-over-year basis. During the same period last year, the company earned $0.25 EPS. On average, analysts expect CareDx to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.

CareDx Trading Down 3.1%

NASDAQ CDNA opened at $14.51 on Tuesday. The stock has a market cap of $772.32 million, a PE ratio of 14.23 and a beta of 2.37. CareDx has a twelve month low of $10.96 and a twelve month high of $26.37. The stock has a fifty day simple moving average of $14.13 and a 200-day simple moving average of $15.78.

Institutional Trading of CareDx

Hedge funds have recently modified their holdings of the stock. Goldman Sachs Group Inc. increased its holdings in CareDx by 18.1% during the 1st quarter. Goldman Sachs Group Inc. now owns 1,110,014 shares of the company’s stock worth $19,703,000 after purchasing an additional 170,504 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its position in shares of CareDx by 11.3% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 133,966 shares of the company’s stock worth $2,378,000 after buying an additional 13,619 shares in the last quarter. JPMorgan Chase & Co. increased its stake in shares of CareDx by 41.2% during the second quarter. JPMorgan Chase & Co. now owns 68,602 shares of the company’s stock worth $1,340,000 after buying an additional 20,028 shares during the period. First Trust Advisors LP acquired a new stake in CareDx in the second quarter valued at approximately $1,822,000. Finally, Nebula Research & Development LLC purchased a new position in CareDx in the second quarter worth approximately $281,000.

Analysts Set New Price Targets

A number of equities research analysts have weighed in on CDNA shares. Weiss Ratings reiterated a “sell (d+)” rating on shares of CareDx in a research report on Wednesday, October 8th. William Blair assumed coverage on shares of CareDx in a report on Tuesday, August 26th. They issued a “market perform” rating for the company. Craig Hallum cut their target price on CareDx from $40.00 to $26.00 and set a “buy” rating on the stock in a research report on Friday, July 18th. Wall Street Zen lowered CareDx from a “hold” rating to a “sell” rating in a research report on Tuesday. Finally, Zacks Research downgraded CareDx from a “hold” rating to a “strong sell” rating in a report on Monday, October 20th. Four equities research analysts have rated the stock with a Buy rating, three have given a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat, CareDx currently has a consensus rating of “Hold” and a consensus target price of $25.50.

About CareDx

CareDx, Inc engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients.